Aurobindo Pharma to stop molnupiravir trial in moderate COVID-19 patients

Merck earlier this year suspended its own development of molnupiravir as a treatment for hospitalized COVID-19 patients since many of them have reached a phase of the disease that is too late for an antiviral drug to provide much help.

from Moneycontrol Business News https://ift.tt/3mGfNo7